Skip to content

Genetics and monogenic forms

TL;DR — Blood pressure is polygenic in the extreme and monogenic in the informative tail. The largest single-stage genome-wide association study, 1,028,980 European-ancestry individuals, reported 2,103 independent signals including 113 novel loci, together explaining more than 60% of SNP-based blood-pressure heritability; the top versus bottom polygenic-score deciles differed by 16.9 mm Hg systolic (95% CI 15.5–18.2) and more than sevenfold in hypertension odds (OR 7.33, 95% CI 5.54–9.70) (Keaton 2024, PMID 38689001). Rare-variant analysis in ~1.3 million participants added 106 new regions and 87 rare-variant associations whose average effects were about eight times larger than common-variant effects (Surendran 2020, PMID 33230300). Against that, twin and family heritability is only ~40% and genomic-relatedness estimates in one cohort gave 20%/50% systolic/diastolic in European ancestry and 27%/39% in African ancestry (Salfati 2015, PMID 26162070) — so genetics explains a large fraction of variance and, so far, almost none of practice. The exception is direction: every Mendelian hypertension syndrome identified alters renal salt handling, which is the strongest available argument that the kidney sets the operating point (Lifton 2001, PMID 11239411).

Heritability

Design Estimate Source
Twin/family studies, conventional ~40% (Salfati 2015, PMID 26162070)
Genomic relatedness, European ancestry (ARIC) ~20% systolic / ~50% diastolic (Salfati 2015, PMID 26162070)
Genomic relatedness, African ancestry (ARIC) ~27% systolic / ~39% diastolic (Salfati 2015, PMID 26162070)
Daytime ambulatory BP, extended twin design Substantial and comparable to office measures (Kupper 2005, PMID 15557390)
Youth, African- vs European-American Differs by ancestry and haemodynamic component (Snieder 2003, PMID 12719445)
Multigenerational Arab pedigrees, ambulatory and beat-to-beat Heritable across measurement modalities (Albarwani 2012, PMID 22967944)

Most of the heritability sits in non-coding, DNase-I-hypersensitive regions and in loci that do not contain previously known cardiovascular or renal genes (Salfati 2015, PMID 26162070) — a finding that anticipated the regulatory architecture the large GWAS later confirmed.

Common-variant architecture

  • Scale. 2,103 independent signals; 113 loci novel; >60% of SNP-heritability explained; 500 genes newly implicated (Keaton 2024, PMID 38689001).
  • Rare variants. 106 new regions and 87 rare-variant associations (44% coding), with effect sizes ~8× common-variant effects, implicating candidate causal genes including GATA5 and PLCB3; BP-associated variants were enriched in active chromatin of fetal tissues, linking developmental programming to later blood pressure (Surendran 2020, PMID 33230300).
  • A worked mechanistic locus. SH2B3/LNK is a blood-pressure and autoimmunity locus; knock-in of the risk polymorphism promoted hypertension and renal damage in mice, giving a rare closed loop from GWAS signal to mechanism (Alexander 2022, PMID 36169218).
  • Gene–environment interaction. Genome-wide gene–sodium and gene–potassium interaction analyses in the GenSalt feeding study identify loci whose effects appear only under altered intake (Li 2016, PMID 27271309; Li 2017, PMID 29212900).
  • Single-cell context. Transcriptomic profiling of peripheral blood mononuclear cells is being used to assign blood-pressure GWAS signals to cell types (Zhang 2025, PMID 40877473).

Polygenic risk scores

Score Population Performance Source
BP PRS from 1.03M European GWAS Independent European dataset Decile 10 vs 1: 16.9 mm Hg systolic difference; hypertension OR 7.33; AUROC 0.791 → 0.826 (ΔAUROC 0.035) (Keaton 2024, PMID 38689001)
HTN-PRS ("PRSsum" of SBP, DBP, HTN scores) 52,436 people, diverse cohorts; validated in 40,201 Associated with prevalent and incident hypertension, and with incident coronary disease, ischaemic stroke, type 2 diabetes and CKD (Kurniansyah 2022, PMID 35729114)
SBP PRS (1,084,157 variants) 3,745 Black ALLHAT/GenHAT participants on chlorthalidone Lowest vs median quintile: ΔSBP −10.01 (95% CI −11.11 to −8.90) vs −6.57 (−7.67 to −5.48) mm Hg over 6 months; no association with lisinopril response; top quintile 67% higher odds of apparent treatment-resistant hypertension (OR 1.67, 1.19–2.36) (Armstrong 2024, PMID 39441603)
Genetic risk score, Swedish cohort Malmö Predicts BP change over time and incident hypertension (Fava 2013, PMID 23232644)
Life-course PRS Bogalusa Heart Study Associations present from childhood through adulthood (Sun 2022, PMID 36011384)
BP PRS Northeast Asian individuals Associated with hypertension risk outside European ancestry (Kim 2026, PMID 41467372)

The chlorthalidone result is the closest anything in this literature has come to actionability — a ~3.5 mm Hg difference in six-month response between genetic-risk strata, drug-specific, and independently validated (Armstrong 2024, PMID 39441603). It is still not a treatment-selection tool: the effect is smaller than the between-drug differences already available for free, and it was derived in one ancestry group within one trial. Portability across ancestries remains the field's structural problem (Krieger 2026, PMID 42395874), though the 1M-participant score did show significant association in a large African American sample (Keaton 2024, PMID 38689001). PRS have also been applied to predict which people with diabetes benefit from intensive blood-pressure control (Tremblay 2021, PMID 34226943) and to anticipate bevacizumab-induced hypertension in oncology (Quintanilha 2022, PMID 35527502).

Monogenic forms

Syndrome Gene(s) Physiology Renin Potassium Treatment implication
Liddle syndrome SCNN1B, SCNN1G (PY motif) ENaC escapes Nedd4-2-mediated retrieval → constitutive Na⁺ reabsorption Suppressed Low Amiloride/triamterene, not spironolactone (Schild 1996, PMID 8665845; Nesterov 2016, PMID 27170740)
Pseudohypoaldosteronism type II (Gordon) WNK1, WNK4, KLHL3, CUL3 Impaired degradation of WNK kinases → NCC hyperactivity Suppressed High Thiazides (Shibata 2013, PMID 23576762; O'Shaughnessy 2015, PMID 25503323; Peces 2023, PMID 37895227)
Apparent mineralocorticoid excess, GRA, others Mineralocorticoid pathway genes Inappropriate MR activation Suppressed Low Pathway-specific (Lifton 2001, PMID 11239411; Bérard 2008, PMID 18448411)
Familial hyperaldosteronism Aldosterone-synthase regulation Autonomous aldosterone Suppressed Low/normal See secondary hypertension (Scholl 2021, PMID 33599784)

Liddle syndrome continues to be identified by new loss-of-regulation mutations across all three ENaC subunits, in families worldwide (Fan 2019, PMID 31437854; Wang 2022, PMID 35661050; Kozina 2019, PMID 31655555; Mareš 2021, PMID 34223773; Uehara 1998, PMID 9794716), and the epithelial sodium channel is increasingly framed as a general drug target rather than a rare-disease curiosity (Lemmens-Gruber 2023, PMID 37175488). Gordon syndrome's genotype–phenotype correlations remain imperfect (Anglani 2022, PMID 34089516; Glover 2013, PMID 23683032), and its acid-base phenotype has prompted reclassification arguments (Adachi 2023, PMID 37081692). The mirror-image evidence — rare SLC12A1/NKCC2 variants with impaired transport function and lower blood pressure — closes the causal argument in the opposite direction (Monette 2011, PMID 21209010).

When to suspect a monogenic cause: early-onset hypertension with a strong family history, suppressed renin with either hypokalaemia (Liddle, mineralocorticoid excess) or hyperkalaemia with metabolic acidosis and normal renal function (Gordon), or a drug-response pattern that does not fit — for example, hypertension responsive to amiloride but not spironolactone.

Mendelian randomisation

Genetic instruments for blood pressure have been used to test causality against outcomes that observational data cannot cleanly resolve. Genetically predicted systolic pressure was associated with valvular heart disease, supporting a causal role (Nazarzadeh 2019, PMID 31290937). Multivariable Mendelian randomisation within the rare-variant meta-analysis suggested possible inverse effects of elevated systolic and diastolic pressure on large-artery stroke, an unexpected result the authors flagged rather than smoothed over (Surendran 2020, PMID 33230300). Genetic instruments have also been used to test lifetime-exposure hypotheses in cardiometabolic multimorbidity (Li 2025, PMID 40481456) and intracerebral haemorrhage (Larsson 2024, PMID 38716647).

Pharmacogenomics beyond PRS

Candidate-gene pharmacogenomics for antihypertensives has a long history and a thin yield (Eadon 2018, PMID 29888336; Xiao 2022, PMID 36329971), with genotype-guided hydralazine an example of the individual-drug approach (Collins 2020, PMID 32927458) and calcium-channel-blocker-directed strategies under exploratory evaluation (Deng 2026, PMID 42553612). Loop-diuretic response has been examined for SNP interactions across ethnic groups (de las Fuentes 2013, PMID 24400021). No genotype-guided antihypertensive strategy has been shown in a randomised trial to improve outcomes.

Open questions

  • Why does a polygenic score explaining >60% of SNP heritability and separating deciles by 16.9 mm Hg still add only 0.035 to AUROC for hypertension prediction? (Keaton 2024, PMID 38689001)
  • Is the chlorthalidone-specific PRS response signal replicable outside Black ALLHAT participants, and large enough to beat a coin-flip between first-line drugs? (Armstrong 2024, PMID 39441603)
  • The enrichment of blood-pressure variants in fetal-tissue active chromatin implies developmental programming — is there any intervention window that follows from it? (Surendran 2020, PMID 33230300)
  • Should suppressed-renin hypertension trigger genetic evaluation rather than just biochemical evaluation, given how many monogenic forms present that way? (Lifton 2001, PMID 11239411; Bérard 2008, PMID 18448411)
  • How much of the ancestry gap in PRS performance is discovery-sample composition and how much is genuine architecture difference? (Kurniansyah 2022, PMID 35729114; Krieger 2026, PMID 42395874)

References

  1. Keaton JM, et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56:778-791. PMID 38689001
  2. Surendran P, et al. Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nat Genet. 2020;52:1314-1332. PMID 33230300
  3. Salfati E, et al. Direct Estimates of the Genomic Contributions to Blood Pressure Heritability within a Population-Based Cohort (ARIC). PLoS One. 2015;10:e0133031. PMID 26162070
  4. Lifton RP, et al. Molecular mechanisms of human hypertension. Cell. 2001;104:545-56. PMID 11239411
  5. Kupper N, et al. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension. 2005;45:80-5. PMID 15557390
  6. Snieder H, et al. Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension. 2003;41:1196-201. PMID 12719445
  7. Albarwani S, et al. Heritability of ambulatory and beat-to-beat office blood pressure in large multigenerational Arab pedigrees. Twin Res Hum Genet. 2012;15:753-8. PMID 22967944
  8. Alexander MR, et al. A Single Nucleotide Polymorphism in SH2B3/LNK Promotes Hypertension Development and Renal Damage. Circ Res. 2022;131:731-747. PMID 36169218
  9. Li C, et al. Genome-Wide Gene-Sodium Interaction Analyses on Blood Pressure: GenSalt. Hypertension. 2016;68:348-55. PMID 27271309
  10. Li C, et al. Genome-Wide Gene-Potassium Interaction Analyses on Blood Pressure: GenSalt. Circ Cardiovasc Genet. 2017;10. PMID 29212900
  11. Zhang H, et al. Deciphering genetic associations with blood pressure in peripheral blood mononuclear cells through single-cell transcriptomic profiling. Hypertens Res. 2025;48:2969-2978. PMID 40877473
  12. Kurniansyah N, et al. A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood. Nat Commun. 2022;13:3549. PMID 35729114
  13. Armstrong ND, et al. Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response. JAMA Cardiol. 2024;9:1134-1141. PMID 39441603
  14. Fava C, et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension. 2013;61:319-26. PMID 23232644
  15. Sun X, et al. Life-Course Associations between Blood Pressure-Related Polygenic Risk Scores and Hypertension in the Bogalusa Heart Study. Genes (Basel). 2022;13. PMID 36011384
  16. Kim NY, et al. Associations Between Polygenic Risk Score for Blood Pressure and Risk of Hypertension in Northeast Asian Individuals. J Am Heart Assoc. 2026;15:e045433. PMID 41467372
  17. Krieger JE. Polygenic risk score translation across diverse populations. Front Cardiovasc Med. 2026;13:1870807. PMID 42395874
  18. Tremblay J, et al. Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia. 2021;64:2012-2025. PMID 34226943
  19. Quintanilha JCF, et al. Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab-Induced Hypertension. Clin Pharmacol Ther. 2022;112:364-371. PMID 35527502
  20. Schild L, et al. Identification of a PY motif in the epithelial Na channel subunits. EMBO J. 1996;15:2381-7. PMID 8665845
  21. Nesterov V, et al. In Liddle Syndrome, Epithelial Sodium Channel Is Hyperactive Mainly in the Early Part of the Aldosterone-Sensitive Distal Nephron. Hypertension. 2016;67:1256-62. PMID 27170740
  22. Shibata S, et al. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proc Natl Acad Sci U S A. 2013;110:7838-43. PMID 23576762
  23. O'Shaughnessy KM. Gordon Syndrome: a continuing story. Pediatr Nephrol. 2015;30:1903-8. PMID 25503323
  24. Peces R, et al. A Spanish Family with Gordon Syndrome Due to a Variant in the Acidic Motif of WNK1. Genes (Basel). 2023;14. PMID 37895227
  25. Bérard E. Contribution of monogenic hypertension models to understanding of other hypertensions. Nephrol Ther. 2008;4:312-9. PMID 18448411
  26. Scholl UI. Hyperaldosteronism. Internist (Berl). 2021;62:245-251. PMID 33599784
  27. Fan P, et al. Truncated Epithelial Sodium Channel β Subunit Responsible for Liddle Syndrome in a Chinese Family. Kidney Blood Press Res. 2019;44:942-949. PMID 31437854
  28. Wang X, et al. A Family with Liddle Syndrome Caused by a Novel Stop-Gain Mutation in the γ Subunit of Epithelial Sodium Channels. Nephron. 2022;146:647-651. PMID 35661050
  29. Kozina AA, et al. Liddle syndrome due to a novel mutation in the γ subunit of ENaC in a family from Russia. BMC Nephrol. 2019;20:389. PMID 31655555
  30. Mareš Š, et al. A novel nonsense mutation in the β-subunit of the epithelial sodium channel causing Liddle syndrome. Blood Press. 2021;30:291-299. PMID 34223773
  31. Uehara Y, et al. Genetic analysis of the epithelial sodium channel in Liddle's syndrome. J Hypertens. 1998;16:1131-5. PMID 9794716
  32. Lemmens-Gruber R, et al. The Epithelial Sodium Channel-An Underestimated Drug Target. Int J Mol Sci. 2023;24. PMID 37175488
  33. Anglani F, et al. Genotype-phenotype correlation in Gordon's syndrome. J Nephrol. 2022;35:859-862. PMID 34089516
  34. Glover M, et al. Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney. Clin Exp Pharmacol Physiol. 2013;40:876-84. PMID 23683032
  35. Adachi M, et al. Classification of pseudohypoaldosteronism type II as type IV renal tubular acidosis. Endocr J. 2023;70:723-729. PMID 37081692
  36. Monette MY, et al. Rare mutations in the human Na-K-Cl cotransporter (NKCC2) associated with lower blood pressure. Am J Physiol Renal Physiol. 2011;300:F840-7. PMID 21209010
  37. Nazarzadeh M, et al. Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study. JAMA Cardiol. 2019;4:788-795. PMID 31290937
  38. Li D, et al. Causal association of modifiable factors with cardiometabolic multimorbidity. Cardiovasc Diabetol. 2025;24:241. PMID 40481456
  39. Larsson SC, et al. Risk Factors for Intracerebral Hemorrhage: Genome-Wide Association Study and Mendelian Randomization Analyses. Stroke. 2024;55:1582-1591. PMID 38716647
  40. Eadon MT, et al. Pharmacogenomic studies of hypertension. Expert Rev Precis Med Drug Dev. 2018;3:33-47. PMID 29888336
  41. Xiao ZL, et al. Personalized antihypertensive treatment guided by pharmacogenomics in China. Cardiovasc Diagn Ther. 2022;12:635-645. PMID 36329971
  42. Collins KS, et al. Genotype-Guided Hydralazine Therapy. Am J Nephrol. 2020;51:764-776. PMID 32927458
  43. Deng K, et al. Association of a CCB-Related Pharmacogenomics-Guided Strategy with Blood Pressure Outcomes. Drug Healthc Patient Saf. 2026;18:637282. PMID 42553612
  44. de las Fuentes L, et al. The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front Genet. 2013;4:304. PMID 24400021